{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:02:06Z","timestamp":1793048526069,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hepatitis C virus (HCV) infection is a major global health threat, with serious consequences including liver cirrhosis and cancer. Despite efforts to combat HCV, an estimated 1.5 million new infections occur each year and HCV was the sixth leading cause of death in 2017. Nevertheless, political leaders are increasingly interested in the fight against HCV, and the achievements of countries such as Rwanda, Egypt, India, Mongolia, Pakistan, Georgia, and Ukraine have given hope that the elimination plan to reduce new infections to 90% and mortality to 65% by 2030 is possible. It is true that some African countries can attest to the difficulty of operationalizing the HCV program with expensive testing platforms and HCV drugs that few could afford in the past, let alone the logistics involved, given that active case detection is an asset for HCV elimination. The inability to add direct-acting antivirals (DAAs) to the national essential drug list and negotiate DAA cost subsidies remains a major challenge in Africa. The lessons learned from implementing and scaling up the human immunodeficiency virus program can provide a strong framework to deliver comprehensive HCV services. We present the strategies used by some African countries to move toward HCV elimination, describe the challenges they have faced, and suggest realistic solutions.<\/jats:p>","DOI":"10.1093\/infdis\/jiad088","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:00:36Z","timestamp":1694624436000},"page":"S221-S225","source":"Crossref","is-referenced-by-count":7,"title":["Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan Africa"],"prefix":"10.1093","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9408-7685","authenticated-orcid":false,"given":"Justine","family":"Umutesi","sequence":"first","affiliation":[{"name":"IHDPC Rwanda Biomedical Centre , Kigali , Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-1900","authenticated-orcid":false,"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Medicine and Center of Excellence for Metabolic-Associated Fatty Liver Disease, National Sun Yat-sen University"},{"name":"Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University , Kaohsiung , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufunmilayo","family":"Lesi","sequence":"additional","affiliation":[{"name":"Global HIV, Hepatitis and STIs Programmes, World Health Organization , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Ward","sequence":"additional","affiliation":[{"name":"Coalition for Global Hepatitis Elimination, Task Force for Global Health"},{"name":"Hubert Department of Global Health, Rollins School of Public Health, Emory University , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janvier","family":"Serumondo","sequence":"additional","affiliation":[{"name":"IHDPC Rwanda Biomedical Centre , Kigali , Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"2023091317000100000_jiad088-B1","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/liv.14222","article-title":"Innovative strategies for the elimination of viral hepatitis at a national level: a country case series","volume":"39","author":"Schr\u00f6eder","year":"2019","journal-title":"Liver Int"},{"key":"2023091317000100000_jiad088-B2","author":"World Health Organization","year":"2020"},{"key":"2023091317000100000_jiad088-B3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrgastro.2013.179","article-title":"HCV transmission in industrialized countries and resource-constrained areas","volume":"11","author":"Thursz","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2023091317000100000_jiad088-B4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S2468-1253(21)00224-7","article-title":"Hepatitis C virus in sub-Saharan Africa: a long road to elimination","volume":"6","author":"Shah","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2023091317000100000_jiad088-B5","volume-title":"Prevention and control of viral hepatitis infection: framework for global action","author":"World Health Organization (WHO)","year":"2012"},{"key":"2023091317000100000_jiad088-B6","author":"World Health Organization (WHO)","year":"2016"},{"key":"2023091317000100000_jiad088-B7","author":"World Health Organization Regional Office for Africa","year":"2019"},{"key":"2023091317000100000_jiad088-B8","author":"Coalition for Global Hepatitis Elimination","year":"2022"},{"key":"2023091317000100000_jiad088-B9","author":"Coalition for Global Hepatitis Elimination","year":"2020"},{"key":"2023091317000100000_jiad088-B10","author":"Coalition for Global Hepatitis Elimination","year":"2022"},{"key":"2023091317000100000_jiad088-B11","first-page":"1","author":"Coalition for Global Hepatitis Elimination","year":"2020"},{"key":"2023091317000100000_jiad088-B12","author":"Coalition for Global Hepatitis Elimination","year":"2022"},{"key":"2023091317000100000_jiad088-B13","author":"Coalition for Global Hepatitis Elimination","year":"2020"},{"key":"2023091317000100000_jiad088-B14","author":"Coalition for Global Hepatitis Elimination","year":"2020"},{"key":"2023091317000100000_jiad088-B15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jhep.2019.03.011","article-title":"Rwanda launches a 5-year national hepatitis C elimination plan: a landmark in sub-Saharan Africa","volume":"70","author":"Umutesi","year":"2019","journal-title":"J Hepatol"},{"key":"2023091317000100000_jiad088-B16","author":"World Health Organization (WHO)","year":"2009"},{"key":"2023091317000100000_jiad088-B17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s12879-017-2422-9","article-title":"Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda","volume":"17","author":"Umutesi","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2023091317000100000_jiad088-B18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/M17-0118","article-title":"Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers a nonrandomized clinical trial","volume":"167","author":"Kattakuzhy","year":"2017","journal-title":"Ann Intern Med"},{"key":"2023091317000100000_jiad088-B19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174148","article-title":"\u201cWaiting for DAAs\u201d: a retrospective chart review of patients with untreated hepatitis C in Rwanda","volume":"12","author":"Gupta","year":"2017","journal-title":"PLoS One"},{"key":"2023091317000100000_jiad088-B20","author":"Clinton Health Access Initiative","year":"2021"},{"key":"2023091317000100000_jiad088-B21","author":"World Health Organization (WHO)","year":"2022"},{"key":"2023091317000100000_jiad088-B22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40121-021-00576-7","article-title":"Sofosbuvir\/velpatasvir for hepatitis C virus infection: real-world effectiveness and safety from a nationwide registry in Taiwan","volume":"11","author":"Cheng","year":"2022","journal-title":"Infect Dis Ther"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_3\/S221\/51544024\/jiad088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_3\/S221\/51544024\/jiad088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T17:00:42Z","timestamp":1694624442000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/Supplement_3\/S221\/7273009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":22,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2023,9,13]]},"published-print":{"date-parts":[[2023,9,13]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad088","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,15]]},"published":{"date-parts":[[2023,9,13]]}}}